Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422878 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5551731 | 0.82 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL17878838 | 0.82 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14422879 | 0.81 | PTGS2 (0.57) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL19798166 | 0.81 | MKNK1 (0.49) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13114284 | 0.80 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14422875 | 0.80 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL12534461 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL28319282 | 0.79 | PTGS2 (0.95) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL322010 | 0.78 | PTGS2 (0.88) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185116-A1 | Bicyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185116-A1 | Bicyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185116-A1 | Bicyclic compounds | KCNN3, KCNJ1, KCNJ2 | PTGS2 962/4885PTGS1 1202/4885ABCC4 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.